Gonorrhoea Resistance Assessment by Nucleic Acid Detection (GRANDII)

Summary

Three sexual health clinical services across Australia and their associated pathology testing laboratories are implementing a new management program for gonorrhoea infection. The services are implementing the use of gonorrhoea drug resistance testing as part of routine clinical and laboratory practice, where drug resistance test results are provided to clinicians quickly to guide choice of antibiotic therapy. Clinicians will identify gonorrhoea infection that is ciprofloxacin susceptible so that it can be treated with ciprofloxacin therapy, rather than ceftriaxone.

Conditions

• Drug Resistance, Microbial
• Antimicrobial Stewardship
• Gonorrhea

Interventions

OTHER

Resistance guided treatment for gonorrhoea infection

For cases of gonorrhoea infection treated at the return visit, a nucleic acid assay will be used to determine individual eligibility for ciprofloxacin treatment

Sponsors & Collaborators

• Kirby Institute

  collaborator OTHER_GOV

• Monash University

  collaborator OTHER

• South Australian Health and Medical Research Institute

  collaborator OTHER

• University of Melbourne

  collaborator OTHER

• University of California, Los Angeles

  collaborator OTHER

• Griffith University

  collaborator OTHER

• Queensland Health

  collaborator OTHER_GOV

• St Vincent's Hospital, Sydney

  collaborator OTHER

• SpeeDx Pty Ltd

  collaborator INDUSTRY

• NSW Health Pathology

  collaborator UNKNOWN

• University of Sydney

  collaborator OTHER

• The University of Queensland

  lead OTHER

Principal Investigators

• David Whiley, PhD · The University of Queensland

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SEQUENTIAL

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-04-26

Primary Completion

2023-07-30

Completion

2024-07-30

Countries

• Australia

Study Locations